News | Deal AnnouncementSVB Securities Serves as Joint Bookrunner for Oculis Holding AG’s (Nasdaq: OCS) $40 Million Follow-On OfferingJune 2023
News | Deal AnnouncementSVB Securities Serves as Lead-Left Bookrunner for HOOKIPA Pharma’s (Nasdaq: HOOK) $50 Million Follow-On OfferingJune 2023
News | Deal AnnouncementSVB Securities Serves as Lead-Left Bookrunner for Belite Bio’s (Nasdaq: BLTE) $30 Million Follow-On OfferingMay 2023
News | Deal AnnouncementSVB Securities Serves as Joint Bookrunner for Guardant Health’s (Nasdaq: GH) $350 Million Follow-On OfferingMay 2023
News | Deal AnnouncementSVB Securities Serves as Lead Capital Markets Advisor and Lead Placement Agent to Forbion European Acquisition Corp. (Nasdaq: FRBN) in Connection with Its Proposed Merger with enGene, Inc. and $135 Million FinancingMay 2023
News | Deal AnnouncementSVB Securities Serves as Joint Bookrunner for agilon health’s (Nasdaq: AGL) $1,868 Million Follow-On OfferingMay 2023
News | Deal AnnouncementSVB Securities Serves as Lead Placement Agent for Eledon Pharmaceuticals’ (Nasdaq: ELDN) Up to $185 Million Private PlacementMay 2023
News | Deal AnnouncementSVB Securities Serves as Financial Advisor to Assertio (NASDAQ: ASRT) on its Pending Acquisition of Spectrum (NASDAQ: SPPI) in an All-Stock and CVR TransactionApril 2023
News | Deal AnnouncementSVB Securities Serves as Exclusive Financial Advisor to Human API on its Sale to LexisNexis Risk Solutions, a part of RELX (NYSE: RELX)April 2023
News | Deal AnnouncementSVB Securities Serves as Lead Placement Agent for Applied Therapeutics’ (Nasdaq: APLT) $30.0 Million Private PlacementApril 2023
News | Deal AnnouncementSVB Securities Serves as Joint Bookrunner for Vaxcyte’s (Nasdaq: PCVX) $500 Million Follow-On OfferingApril 2023
News | Deal AnnouncementSVB Securities Serves as Exclusive Financial Advisor to MedStream Anesthesia on Its Sale to National Partners in HealthcareApril 2023
